Is there an estrogenic component in the metabolic syndrome?

Starcke, S.; Vollmer, Günter

doi:10.1007/bf02829967

Cited by 8 publications

(3 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result suggests a potential difference in the cardiovascular effect of pioglitazone on males and females. Indeed, pioglitazone is known to influence estrogen function and sex hormone-binding globulin expression [ 35 – 36 ], which may have contributed to the observed gender difference.…”

Section: Discussionmentioning

confidence: 99%

Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study

Seong

Choi²,

Shin

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

Background/ObjectivesData on the comparative effectiveness of oral antidiabetics on cardiovascular outcomes in a clinical practice setting are limited. This study sought to determine whether a differential risk of cardiovascular disease (CVD) exists for the combination of a dipeptidyl peptidase-4 (DPP-4) inhibitor plus metformin versus a sulfonylurea derivative plus metformin or pioglitazone plus metformin.MethodsWe conducted a cohort study of 349,476 patients who received treatment with a DPP-4 inhibitor, sulfonylurea, or pioglitazone plus metformin for type 2 diabetes using the Korean national health insurance claims database. The incidence of total CVD and individual outcomes of myocardial infarction (MI), heart failure (HF), and ischemic stroke (IS) were assessed using the hazard ratios (HRs) estimated from a Cox proportional-hazards model weighted for a propensity score.ResultsDuring follow-up, 3,881 patients developed a CVD, including 428 MIs, 212 HFs, and 1,487 ISs. The adjusted HR with 95% confidence interval (CI) for a sulfonylurea derivative plus metformin compared with a DPP-4 inhibitor plus metformin was 1.20 (1.09-1.32) for total CVD; 1.14 (1.04-1.91) for MI; 1.07 (0.71-1.62) for HF; and 1.51 (1.28-1.79) for IS. The HRs with 95% CI for total CVD, MI, HF, and IS for pioglitazone plus metformin were 0.89 (0.81-0.99), 1.05 (0.76-1.46), 4.81 (3.53-6.56), and 0.81 (0.67-0.99), respectively.ConclusionsCompared with a DPP-4 inhibitor plus metformin, treatment with a sulfonylurea drug plus metformin was associated with increased risks of total CVD, MI, and IS, whereas the use of pioglitazone plus metformin was associated with decreased total CVD and IS risks.

show abstract

Section: Discussionmentioning

confidence: 99%

Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study

Seong

Choi²,

Shin

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…For quite some time, phytoestrogens have become an object of interest as additional treatment option of the metabolic syndrome [3]. Phytoestrogens are secondary plant products and have been named because of their structural and functional similarity to the 17b-estradiol.…”

Section: Introductionmentioning

confidence: 99%

The association between urinary phytoestrogen excretion and components of the metabolic syndrome in NHANES

et al. 2013

View full text Add to dashboard Cite

show abstract

“…It has been suggested that in the UK as many as 25% of the population show clear clinical signs of metabolic syndrome and similar, if not higher, figures are expected to be found in the majority of affluent countries in Europe and Americas. The incidence is higher in certain ethnic subgroups and in specific population groups, and it can also be associated with other physiological and environmental factors35, 36. Owing to this incidence and to the dramatic impact on society, it is considered a major target for nutritional intervention policies directed to the population as a whole.…”

mentioning

confidence: 99%